|Application ||WB, IHC-P, IF, ICC, IP|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||404419 Da|
|Dilution||ICC (1:500), IF (1:500), IHC-P (1:100), WB (1:2000),|
|Other Names||ZFHX3, AT motif-binding factor, Zinc finger homeobox 3, ZNF927, ZFH-3, Zinc finger homeobox protein 3, AT motif-binding factor 1, ATBF1, ATBT|
|Target/Specificity||human ZFHX3 / ATBF1|
|Reconstitution & Storage||PBS, pH 7.2, 50% glycerol. Store at -20°C.|
|Precautions||ZFHX3 / ATBF1 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Transcriptional regulator which can act as an activator or a repressor. Inhibits the enhancer element of the AFP gene by binding to its AT-rich core sequence. In concert with SMAD- dependent TGF-beta signaling can repress the transcription of AFP via its interaction with SMAD2/3 (PubMed:25105025). Regulates the circadian locomotor rhythms via transcriptional activation of neuropeptidergic genes which are essential for intercellular synchrony and rhythm amplitude in the suprachiasmatic nucleus (SCN) of the brain (By similarity). Regulator of myoblasts differentiation through the binding to the AT-rich sequence of MYF6 promoter and promoter repression (PubMed:11312261). Down- regulates the MUC5AC promoter in gastric cancer (PubMed:17330845). In association with RUNX3, upregulates CDKN1A promoter activity following TGF-beta stimulation (PubMed:20599712). Inhibits estrogen receptor (ESR1) function by selectively competing with coactivator NCOA3 for binding to ESR1 in ESR1-positive breast cancer cells (PubMed:20720010).|
|Cellular Location||Nucleus. Cytoplasm. Note=Translocates from the cytoplasm to the nucleus following TGF-beta stimulation. Expressed in nuclear body (NB)-like dots in the nucleus some of which overlap or closely associate with PML body|
|Tissue Location||Not found in normal gastric mucosa but found in gastric carcinoma cells (at protein level). Expression is higher in ER-positive breast tumors than ER-negative breast tumors (at protein level).|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Transcriptional repressor. It inhibits the enhancer element of the AFP gene by binding to its AT-rich core sequence. Regulator of myoblasts differentiation through the binding to the AT-rich sequence of MYF6 promoter and promoter repression. Down- regulates the MUC5AC promoter in gastric cancer.
Miura Y.,et al.J. Biol. Chem. 270:26840-26848(1995).
Morinaga T.,et al.Mol. Cell. Biol. 11:6041-6049(1991).
Martin J.,et al.Nature 432:988-994(2004).
Mural R.J.,et al.Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
Loftus B.J.,et al.Genomics 60:295-308(1999).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.